Together, these functional and genetic data demonstrate that loss of PD-1 tumor-suppressor function results in enhanced ACLY activity via enforced (PI3K)–AKT signaling and that this mechanism is critical for both glucose-dependent histone acetylation and the malignant expansion of PD-1-deficient lymphomatous T cells. The gene discussed is PDCD1; the disease is neoplasm.